Short answer
Cigna (CI) filed its fiscal 2024 10-K annual report with the SEC on Feb 27, 2025. It reported revenue of $247.1B (+26.6% year over year) and net income of $3.4B.
- Top risk flagged: Regulatory/legal risk: Potential credit losses on $9.4B debt securities portfolio amid rising interest rates per FASB's credit loss guidance, monitored in Note 11 disclosures
FY2024 key financial metrics · XBRL
- Revenue
- $247.1B
- +26.6% YoY
- Net income
- $3.4B
- −33.5% YoY
- Operating margin
- 3.8%
- −0.6 pp YoY
- EPS (diluted)
- $12.12
- −30.3% YoY
- ROE
- 8.4%
- −2.8 pp YoY
- Operating cash flow
- $10.4B
- −12.3% YoY
Source: XBRL data from the Cigna (CI) FY2024 10-K on SEC EDGAR. USD.
Cigna FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Health services and insurance with key focus on Medicare and Individual and Family Plan (IFP) customers
- New emphasis on Medicare business expansion reflected by $175 million increase in unpaid claims liability, partially offsetting $300 million decrease in IFP claims
- Strategic shift: Increased Medicare focus aligns with decreased IFP customer base, signaling changing portfolio risk and growth priorities
- Notable quantitative metric: Other Operations revenues up 39% to $828 million; pre-tax adjusted income from operations down to loss of $9 million from $96 million
- Corporate pre-tax adjusted loss steady near $1.7 billion, with lower pension and operating costs partly offset by 6% rise in interest expense
Management Discussion & Analysis
- Revenue details not explicitly disclosed in provided text; focus on Evernorth Health Services and Cigna Healthcare segments described
- Profitability/margin figures not provided for fiscal 2024; no % margins or YoY profit changes disclosed
- Best performing segment implied Evernorth Health Services with integrated Pharmacy Benefit Services and Specialty and Care Services fueling growth
- No segment revenue figures or worst performing segments directly stated in excerpt
- Capital allocation: no specific cash flow, buyback, dividend, or capex numbers disclosed in provided text
- Forward outlook absent; no guidance or key risk details presented in excerpt; pending HCSC transaction noted for Medicare Advantage and related businesses
Risk Factors
- Regulatory/legal risk: Potential credit losses on $9.4B debt securities portfolio amid rising interest rates per FASB's credit loss guidance, monitored in Note 11 disclosures
- Geopolitical/macro risk: $15.6B insurance joint venture in China exposed to geopolitical and economic uncertainties in that market
- Operational/supply chain risk: 25% exposure to stressed office real estate sector in $1.4B commercial mortgage loan portfolio amid shifting work-from-home trends
- Competitive/market disruption risk: Real estate limited partnerships face valuation volatility due to market and portfolio transaction adjustments affecting $4.6B long-term investments
- Financial/structural risk: $1.8B fair value decline in long-term debt under a 100 basis point interest rate increase scenario, indicating sensitivity to rising rates
Generated from the filing text; verify against the original. How to read a 10-K
Other Cigna annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.